Founded in 2009, Fabentech specialises in the development and production of polyclonal antibody treatments for fighting high-priority biological agents which could threaten public health.
Our platform is based on a safe, tested and fully validated polyclonal antibody technology, initially developed by Sanofi Pasteur and enhanced by the Fabentech R&D team for more than a decade. Our Integrated R&D and proprietary manufacturing site enable rapid developments of medical countermeasures against different targets. We are using our expertise to offer reliable protection and treatments ready to face proliferating risks.
Fabentech has over 14 years of experience in the development and production of emergency care solutions and medical countermeasures.
Fabentech’s key milestones
Inception of the company
Phase I Clinical study of FabenFLU® treatment against H5N1 Avian Influenza infection.
Launch of the Ebola Program in collaboration with the World Health Organisation (WHO) and with the support of the European Medicines Agency (EMA).
Orphan drug status (ODD) in Europe for FabenFLU® treatment against H5N1 Avian Influenza infection.
First collaboration with the French Army on a first antidote against a highly lethal plant-based toxin.
Fabentech raises 8.5 million euros led by Definvest, the Armed forces ministry fund managed by Bpifrance, with participation by Institut Mérieux and its historical investors.
Launch of FabenCOV®, an immunotherapy program to treat Covid-19 infections
Sebastien IVA is appointed CEO of Fabentech
Bio-production: Fabentech presents its new industrial site
Fabentech is awarded 9.2 million euros to develop its FabenCOV® treatment against Covid-19 and its variants in the context of European HERA projects
Launch of a new program to treat Nipah virus infection
The company is granted of 5m€ through the COUNTERACT European consortium to launch several biodefence programs funded by the European Defense Fund.
Fabentech can count on the skills and energy of an experienced and mobilised team with strong track records in the pharmaceutical industry.
Sebastien Iva, a seasoned professional with 25 years of experience in the life science industry, is the Chief Executive Officer of Fabentech since 2020.
His journey began at Sanofi in 1996 in marketing and sales roles in Asia. He then joined Stallergenes-Greer, a leading biopharmaceutical company specialized in the field of allergen immunotherapy, as a member of the leadership team. There, he led the set-up and development of international operations in EMEA countries for more than a decade.
Sebastien moved on to the Thuasne Group, a leading medical devices company, where he successfully led the reorganisation of International Operations. Before joining Fabentech as a CEO, he served as the Chief Operating Officer in a Swiss startup dedicated to point-of-care diagnosis of neurological diseases.
Sebastien Iva is graduated from the Burgundy School of Business, HEC (Paris), and INSEAD.
Ludovic Nguyen brings more than 20 years of expertise in the pharmaceutical field to his role as Chief Operating Officer at Fabentech. Starting his career as a project manager for industrialisation and development at Sanofi Pasteur, before taking on high-responsibility roles in immunoglobulin production.
In 2014, Ludovic joined Fabentech and was responsible for the creation of the production site and laboratories. As the company grew, he became Head of Industrial Operations and successfully launched our state-of-the-art production site in 2020. In 2023, he was appointed Chief Operating Officer, supervising strategic projects while keeping his responsibilities of Head of Industrial Operations.
Ludovic holds an engineering degree in process and a Master’s in process engineering from the National Polytechnic Institute of Lorraine.
Antoine Gaillard is a Pharmacist, holding a specialised complementary Master’s degree in industrial pharmacy. In 2014, he began his career at Sanofi in the Corporate Department of Pharmacovigilance & Epidemiology, where he was involved in establishing PV agreements between Sanofi and its international partners to meet regulatory requirements.
Over the years, Antoine has held several positions of responsibility, including at Nextpharma, where he served as a Qualified Person for multiple years. This experience has allowed him to gain in-depth knowledge of product quality, authorised operations of a pharmaceutical establishment, and the regulatory environment.
Drawing on his skills and expertise, Antoine joined Fabentech in 2021 as the Responsible Pharmacist. His regulatory and pharmaceutical requirements expertise brings a strategic contribution to the company’s board of directors.
Sophia Mery is the Head of Finance at Fabentech, where she joined in 2021. With 7 years of experience in corporate finance, Sophia began her career at Deloitte, where she gained significant financial knowledge auditing a variety of listed and unlisted companies, as well as diverse institutions in industries such as healthcare, public institutions, and more. Her experience auditing pharmaceutical companies ignited her passion for this field.
During her time at Deloitte, Sophia also honed her managerial skills, leading several teams of financial auditors.
She holds a master’s degree in Audit and Corporate Finance from ESDES (UCLY) Business School and a Diploma in Advanced Studies in Accounting and Management (DSCG).
Gregory Vernier is Head of Business Development at Fabentech, taking on the role in 2021. With 18 years of experience in the life sciences field, Gregory brings extensive expertise in business development activities. Researcher by training, he has worked in research activities at prestigious universities such as Harvard Medical School and gained invaluable international experience. He has also led a business association in the healthcare industry for over 8 years.
Gregory holds a PhD in Biochemistry, which he complemented with a Master’s degree in business studies and a certificate in corporate finance from HEC Paris.
Nathan Le Meur is currently serving as the Head of Regulatory Affairs at Fabentech since 2020. With over six years of experience at Sanofi Pasteur, Nathan has successfully executed regulatory strategies on an international scale. He works in close collaboration with the Fabentech team and public health authorities to ensure that the company’s products meet the highest quality, safety, and efficacy standards.
Nathan holds a Master’s degree in Technical and Regulatory Affairs, complemented by a management training at EM Lyon Business School.
Laure Planche is Head of Processes and Products Industrialization at Fabentech. Since joining the company in 2017, Laure has been instrumental in leading development, tech transfert, validation and life cycle management with a strong Quality by Design mindset. She is active part for A3P expert group on Quality by Design and one of the writer of a guide on implementation of Quality by Design for Industry.
She has over 15 years of experience including 8 years at Sanofi, where she undertook various missions in development, industrialisation, and validation of drug substances and products, gaining valuable experience in process life cycle management.
Laure has also made significant contributions to other renowned pharmaceutical companies such as Sanofi, GSK, Sequens and Baxter. Laure holds a “Master in Infectiology” degree.
Claire Perrin is Head of Quality at Fabentech, where she joined in 2022. With 17 years of experience in the pharmaceutical industry, Claire has worked in several innovative SMEs, implementing their quality systems and building a company-wide quality culture. She has been involved in various missions, gaining essential cross-functional skills for Fabentech : quality support for pharmaceutical and clinical development, Quality Risk Management, Quality by Design, and management.
Claire holds a degree in Chemical Engineering and Process Engineering from CPE Lyon.
Olivier is Doctor of Medicine and holds a Master in Public Health.
Olivier Godeaux joined Fabentech as the Chief Medical Officer in September 2022. With over three decades of experience in the pharmaceutical, biotechnological, and Contract Research Organization fields, Olivier is a well-respected leader in his industry. He has held decision-making positions in several companies, including GSK, Janssen Vaccines, Novadip, Bone Therapeutics and Lamina Therapeutics, where he excelled as Chief Medical Officer.
Olivier’s academic credentials include a Medical Doctor degree and a Master’s degree in Public Health from Université Catholique de Louvain.
Jean-Christophe Audonnet works at Fabentech as scienfitic advisor and acting CSO since 2023. He retired from BioPharma Industry after more than 40 years of experience in animal health & life-sciences in several large pharmaceutical companies such as Merial, Sanofi, Boehringer Ingelheim. He was Coordinator of the Innovative Medicines Initiative ZAPI project from 2015 to 2021. He now owns a consulting company which helps biopharmaceutical companies to grow.
Jean-Christophe holds a PhD and a master in Veterinary Medicine.
- Philippe ArchinardChairman of the supervisory board, Institut Mérieux
- Franck LescureAuriga Partners, a venture capital management firm
- Guillaume HemmerleTrail, a venture capital management firm
- Marielle MailhesBPI France Investissement, Public Bank of Investment
- Sandra DubosKreaxi, an investment management firm, specialised in equity financing of innovative startups
- Bertrand LépineFounder of Fabentech
- Albert SaportaCensor
Fabentech successful team
From public support to research institutes, Fabentech can count on a network of local, national and international partners to participate in the development of its medical countermeasures.